Clinical trials · Georgia
Recurrent Head and Neck Squamous Cell Carcinoma clinical trials in Georgia
We’re tracking 17 recruiting recurrent head and neck squamous cell carcinoma studies with a site in Georgia — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Georgia
- NCT07195734RecruitingPhase 2
Adding chemo or immunotherapy before surgery for advanced head and neck cancer
This trial tests whether giving chemotherapy or chemotherapy plus immunotherapy before surgery can improve outcomes for people with advanced head and neck cancer that has come back or not gone away after prior treatment.
Atlanta, GeorgiaAges 18 years+ - NCT06769698RecruitingPhase 2
Testing fianlimab with cemiplimab for head and neck cancer
This study compares a new combination of two drugs (fianlimab and cemiplimab) against cemiplimab alone for people with head and neck cancer that has returned or spread. It aims to see if the combination works better.
Atlanta, GeorgiaAges 18 years+ - NCT02734537RecruitingPhase 2
Radiation with or without cisplatin after head and neck surgery
This trial studies whether adding cisplatin (a chemotherapy medicine) to radiation therapy helps people with stage III–IVA squamous cell cancer of the head and neck after they’ve had surgery. It’s meant to lower the risk of the cancer coming back.
Atlanta, GeorgiaAges 18 years+ - NCT06980038RecruitingPhase 2
Testing two immunotherapy drugs before surgery for advanced head and neck cancer
This trial tests whether adding a second immunotherapy drug (CDX-1140) to the standard immunotherapy cemiplimab before surgery is better than cemiplimab alone for people with stage III-IV head and neck cancer that can be removed with surgery.
Atlanta, GeorgiaAges 18 years+ - NCT04428671RecruitingPhase 1
Cemiplimab before and after surgery for high-risk skin cancer
This Phase 1 trial tests the drug cemiplimab given before and after surgery to reduce the chance that high-risk cutaneous squamous cell cancer comes back. You may be a candidate if your cancer is high-risk on pathology or imaging and is planned for surgical removal.
Atlanta, GeorgiaAges 18 years+ - NCT07219212RecruitingPhase 1
New drug with chemo and radiation for advanced head and neck cancer
This study tests if adding an investigational drug called JNJ-90301900 to standard chemotherapy and radiation therapy works better for people with certain advanced head and neck cancers (like mouth, throat, and voice box) that have not spread to other parts of the body.
Atlanta, GeorgiaAges 18–74 - NCT03526835RecruitingPhase 1/Phase 2
Study of MCLA-158 for advanced solid tumors
This trial tests a new experimental drug called MCLA-158 (petosemtamab) for people with advanced solid tumors, especially head and neck cancer or colorectal cancer, that have not responded to standard treatments. The study aims to see if this drug can shrink tumors or slow their growth.
Atlanta, GeorgiaAges 18 years+ - NCT04198766RecruitingPhase 1/Phase 2
New OX40 immunotherapy for advanced solid tumors
This trial tests a new immunotherapy drug (INBRX-106) alone or with Keytruda (pembrolizumab) for adults with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug can help the immune system fight cancer.
Atlanta, GeorgiaAges 18 years+ - NCT06662058Recruiting
Remote hearing test for head and neck cancer patients on cisplatin or radiation
This study tests a remote hearing test to monitor hearing changes in patients with head and neck cancer getting cisplatin chemotherapy and/or radiation. The goal is to catch hearing loss early so treatment can be adjusted.
Atlanta, GeorgiaAges 18 years+ - NCT04534205RecruitingPhase 2/Phase 3
Testing BNT113 plus pembrolizumab versus pembrolizumab alone
This trial studies whether adding BNT113 to pembrolizumab works better and is safe for people with HPV16-positive head and neck cancer that can’t be cured with local treatments. It also compares outcomes to pembrolizumab alone, specifically for tumors that show PD-L1 in testing.
Athens, GeorgiaAges 18 years+ - NCT04671667RecruitingPhase 2
Pembrolizumab vs chemo-radiation after surgery for recurrent head/neck cancer
This trial tests whether pembrolizumab (an immunotherapy drug) works better than the usual chemo plus radiation after surgery for cancer that has come back in the head and neck area. It may help reduce cancer returning or spreading by using your immune system, but eligibility depends on how the cancer came back and your prior treatments.
Atlanta, GeorgiaAges 18–79 - NCT06064877RecruitingPhase 3
Study of ficlatuzumab plus cetuximab for advanced head and neck cancer
This trial tests a combination of two drugs, ficlatuzumab and cetuximab, for people with recurrent or metastatic head and neck cancer that is HPV-negative and has not responded to prior immunotherapy and chemotherapy. It aims to see if this combination can help shrink tumors or slow the disease.
Atlanta, GeorgiaAges 18 years+ - NCT06163534Recruiting
Biomarker profiling study for advanced head and neck cancer patients
This study collects blood and tumor tissue samples to analyze biological markers in patients with advanced head and neck squamous cell carcinoma before starting immunotherapy. The goal is to better understand how these markers relate to treatment response.
Atlanta, GeorgiaAges 18 years+ - NCT06525220RecruitingPhase 3
New drug combo vs. standard for head and neck cancer
This trial tests a new combination of two immunotherapy drugs (petosemtamab plus pembrolizumab) compared to pembrolizumab alone for people with head and neck cancer that has spread or come back and cannot be cured locally. It may be an option if your cancer has a certain protein (PD-L1) and you haven't had prior cancer treatment for this stage.
Atlanta, GeorgiaAges 18 years+ - NCT06636734RecruitingPhase 2
Lovastatin plus pembrolizumab for advanced head and neck cancer
This trial tests whether adding lovastatin (a cholesterol-lowering drug) to pembrolizumab (an immunotherapy) works better than pembrolizumab alone for head and neck cancer that has come back or spread. It's for people who haven't had immunotherapy before and aren't already on a statin.
Atlanta, GeorgiaAges 18 years+ - NCT06868433RecruitingPhase 1
TMV vaccine alone or with pembrolizumab for advanced HNSCC
This trial tests a vaccine made from your own tumor to help your immune system fight head and neck cancer that has returned or spread. It is given alone or with an immunotherapy drug (pembrolizumab) to see if it can shrink tumors or slow progression.
Atlanta, GeorgiaAges 18 years+ - NCT04892173RecruitingPhase 3
Radiation plus a tumor injection, with or without cetuximab
This trial studies whether adding a special drug given directly into a head-and-neck tumor during radiation can improve outcomes. It also looks at whether cetuximab (an antibody medicine) should be added for people who cannot or should not have certain standard chemotherapy.
Atlanta, GeorgiaAges 60 years+
Recurrent Head and Neck Squamous Cell Carcinoma trials by city in Georgia
Where these studies are running in Georgia
Institutions with a site for the recruiting recurrent head and neck squamous cell carcinoma studies listed above.
- Emory University · 15 studies
- Emory Midtown University Hospital/Winship Cancer Institute
- Memorial Health University Medical Center
- Morehouse
- Piedmont Healthcare
- Site 171
- University Cancer & Blood Center
What taking part in a recurrent head and neck squamous cell carcinoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Recurrent Head and Neck Squamous Cell Carcinoma trials in other states
Common questions
- Are there recurrent head and neck squamous cell carcinoma clinical trials in Georgia?
- Yes. We're currently tracking 17 recruiting recurrent head and neck squamous cell carcinoma studies with a site in Georgia, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a recurrent head and neck squamous cell carcinoma study in Georgia?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Georgia to take part?
- Not necessarily. These studies have a site in Georgia, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a recurrent head and neck squamous cell carcinoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New recurrent head and neck squamous cell carcinoma studies open in Georgia regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.